Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug ...

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.